Avenue Therapeutics, Inc. financial data

Symbol
ATXI on Nasdaq
Industry
Pharmaceutical Preparations
Location
1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -338 % -167%
Return On Equity -285 %
Return On Assets -137 % +28.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.3 M shares +645%
Common Stock, Shares, Outstanding 590 K shares -91.4%
Entity Public Float 8.52 M USD +189%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 562 K shares +657%
Weighted Average Number of Shares Outstanding, Diluted 8.2 M shares +459%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 7.31 M USD +247%
General and Administrative Expense 4.51 M USD -14.5%
Operating Income (Loss) -11.8 M USD -1.81%
Nonoperating Income (Expense) -641 K USD +45.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -3.55 M USD +4.8%
Earnings Per Share, Basic 85.2 USD/shares +84.8%
Earnings Per Share, Diluted 0.06 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.19 M USD -61.2%
Assets 3.31 M USD -60.8%
Accounts Payable, Current 78 K USD -39.5%
Liabilities, Current 1.41 M USD -86.7%
Liabilities 1.41 M USD -86.7%
Retained Earnings (Accumulated Deficit) -95.3 M USD -8.15%
Stockholders' Equity Attributable to Parent 2.84 M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 1.9 M USD
Liabilities and Equity 3.31 M USD -60.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.12 M USD -98.3%
Net Cash Provided by (Used in) Financing Activities 4.53 M USD +46.1%
Net Cash Provided by (Used in) Investing Activities -3 M USD
Common Stock, Shares Authorized 200 M shares +167%
Common Stock, Shares, Issued 590 K shares -91.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.71 M USD +78.3%
Deferred Tax Assets, Valuation Allowance 35.7 M USD +15.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 35.7 M USD +15.2%
Deferred Tax Assets, Operating Loss Carryforwards 27.3 M USD +6.46%
Preferred Stock, Shares Issued 250 K shares
Preferred Stock, Shares Authorized 2 M shares 0%
Additional Paid in Capital 98.1 M USD +13.2%
Preferred Stock, Shares Outstanding 250 K shares
Share-based Payment Arrangement, Expense 1.09 M USD +1636%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%